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Abstract The role of intestinal bacteria in the patho-
genesis of nonalcoholic fatty liver disease is increasingly
acknowledged. Recently developed microbial profiling
techniques are beginning to shed light on the nature of gut
microbiota alterations in nonalcoholic fatty liver disease. In
this review, we summarize the gut microbiota composition
changes that have been reported during different stages of
human nonalcoholic fatty liver disease, and highlight the
relation between bile acids and gut bacteria in this context.
In addition, we discuss the different methodologies used in
microbiota analyses as well as the interpretation of
microbiota data. Whereas the currently available studies
have provided useful information, future large-scale
prospective studies with carefully phenotyped subjects and
sequential sampling will be required to demonstrate a
causal role of gut microbiota changes in the etiology of
nonalcoholic fatty liver disease.
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Introduction
Nonalcoholic fatty liver disease (NAFLD), the hepatic
manifestation of the metabolic syndrome [1], is charac-
terized by hepatic fat accumulation in the absence of sig-
nificant alcohol consumption, viral infection, or other liver
disorders [2]. NAFLD ranges from simple steatosis to
inflammatory nonalcoholic steatohepatitis (NASH), with or
without fibrosis. It is the most common liver disorder
worldwide, and has an increasing prevalence. NASH, but
not simple steatosis, frequently progresses to life threat-
ening disorders such as cirrhosis and hepatocellular carci-
noma (HCC) [3].
NAFLD pathophysiology is multifactorial, involving
ecological, genetic, and metabolic factors such as limited
physical activity, high energy intake, and a dysbalanced
diet (e.g. too much fructose and/or saturated fat) [4].
Together with epigenetic factors, this promotes insulin
resistance and hepatic fat accumulation [2, 5]. Progression
towards inflammation of the steatotic liver was initially
proposed to be related to endotoxemia as a result of
increased gut permeability by Brun et al. [6] and Wigg
et al. [7]. Subsequently, evidence accumulated that
intestinal microbiota plays an important part in the patho-
genesis of NAFLD [8–10]. Microbial profiling techniques
developed in the past few years enabled major advances in
our understanding of alterations of the gut microbiota and
the role of gut bacteria in the development of NAFLD [11].
This review summarizes these recent findings, focusing
on gut microbiota composition changes during the different
stages of human NAFLD, and paying particular attention to
the methodologies used in microbiota analyses as well as
their interpretation.
Microbiota composition in NAFLD
Steatosis and steatohepatitis
There are only a limited number of studies that have
examined microbiota composition in patients with simple
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steatosis or NASH, and these have very dissimilar results
(Table 1). First of all, patients with NASH were recently
shown to have a decreased abundance of bacteria belonging to
the phylum Bacteroidetes compared to subjects with simple
steatosis and healthy individuals as shown by qPCR [9]. In
contrast, studies using sequencing techniques showed an
increase of Bacteroides, one of the most important genera
within theBacteroidetes phylum, and a decrease of Firmicutes
in NASH patients as compared to healthy subjects [8]. The
lower representation of Firmicutes in NASH patients was
especially due to a reduced abundance of theLachnospiraceae
and Ruminococcaceae families. However, another study
demonstrated an increase of Lachnospiraceae and Lacto-
bacillaceae in NAFLD patients, albeit without distinguishing
Table 1 Significant microbiota composition changes in nonalcoholic liver disease
Disease comparison Samples Microbiota variations
(family_genus)
Techniques References
Non-NASH cirrhotic patients (n = 181) versus NASH







Healthy (n = 17) versus NASH (n = 22) Stool ;Phylum: Bacteroidetes qPCR [7]
Simple steatosis (n = 11) versus NASH (n = 22) Stool ;Phylum: Bacteroidetes
: C. coccoides
qPCR [7]
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between simple steatosis and NASH [10]. Both studies
observed a decrease in members of the Ruminococcaceae
family in NASH [8, 10]. The apparent lack of consistent
changes of gut microbiota composition in NASH is further
exemplified by two recent studies, showing either an over-
representation of the genus Escherichia from the Enterobac-
teriaceae family in subjectswithNASH [8] or no difference in
Escherichia coli abundance in NASH patients compared to
subjects with simple steatosis [9]. Despite the lack of consis-
tent NAFLD-related gut microbiota changes, the possible
overgrowth of these ethanol-producing bacteria may underlie
the increased circulating ethanol levels in NASH [8]. The
endogenous production of ethanolmight, in turn, contribute to
the formation of free fatty acids and oxidative stress (Fig. 1),
further underscoring the potential role of ethanol-producing
bacteria in the pathogenesis of NAFLD.
Large scale trials, designed to identify alterations of
microbiota composition in patients with simple steatosis
versus NASH, are required to shed more light on the nature
of the gut microbiota shifts characteristic of specific stages
of NAFLD. These trials should also pay attention to the
fact that most NAFLD patients are obese, since obesity
itself is linked to gut microbiota composition changes, as
reviewed elsewhere [12, 13]. Future studies should ideally
include obese non-NAFLD patients or non-obese NAFLD
patients [14] to exclude the impact of obesity, or control for
obesity in statistical analyses. It should be further noticed
that many studies so far excluded all taxa with an abun-
dance below 1 %. However, even low-abundant bacteria
such as Akkermansia muciniphila have the potential to
profoundly affect host metabolism [15]. In addition, with-
out any fundamental direct evidence provided by fecal
transplantation or antibiotic studies, one cannot exclude
that the described alterations in the intestinal microbiota
are a consequence rather than a cause of liver disease.
Fibrosis and cirrhosis
Surprisingly little evidence exists to date for an effect of
gut microbiota on liver fibrosis. However, very recently, an
elegant study was published showing that in a bile duct












































Fig. 1 Mechanisms by which gut bacteria affect the hallmarks of
nonalcoholic fatty liver disease. SCFAs short-chain fatty acids,
PAMPs pathogen associated molecular patterns, ROS reactive oxygen
species, FFAs free fatty acids, Tg triglyceride, LPS lipopolysaccha-
ride, TLR Toll-like receptor, SIBO small intestinal bacterial
overgrowth, TGF-b transforming growth factor-b, IL-6 interleukin-
6, TNF-a tumor necrosis factor-a, HSCs hepatic stellate cells, Fiaf
fasting induced adipocyte factor, Lpl lipoprotein lipase, VLDL very
low density lipoprotein, GLP-1 glucagon-like peptide-1
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gut microbiota of mice fed a high fat diet (HFD) aggra-
vated fibrosis relative to transplanting gut microbiota of
mice fed chow [16]. This was mainly attributable to an
increased abundance of Gram-negative Proteobacteria; a
marked decrease of Bifidobacteriaceae was also observed.
Specific bacteria of both the Proteobacteria and Firmicutes
phyla produce enzymes catalyzing choline conversion into
methylamines [17]. The latter may promote liver inflam-
mation via the portal vein, and decreased choline levels
have already been associated with fibrosis progression [18].
However, future studies should ascertain to what extent the
described microbiota composition changes in fibrosis affect
choline metabolism.
Cirrhosis patients often have a higher proportion of
potentially pathogenic bacteria and a reduction of auto-
chthonous (resident) bacteria compared to healthy indi-
viduals (Table 2) [19–21]. Common differences include a
decrease in families with the potential to convert primary
into secondary bile salts (Lachnospiraceae and Ru-
minococcaceae) in cirrhosis, and overgrowth of the Gram-
negative Enterobacteriaceae family, similar to what is
observed in NASH [22]. This suggests that bile salts and
endotoxin [23] may play a role in the pathogenesis of
cirrhosis. Additional gut microbiota changes in patients
with cirrhosis include a decrease in Clostridiales XIV and
an increase in Enterococcaceae and Staphylococcaeae [19]
as well as overgrowth of Veillonellaceae [21].
Another cohort of cirrhotic patients revealed a decrease
of the genera Bacteroides, Eubacterium, and Alistipes,
whereas Clostridium and Prevotella were increased com-
pared to healthy controls [24]. However, the most abun-
dantly enriched species in these cirrhotic patients belonged
to the Streptococcus and Veillonella genera. Remarkably,
these genera comprise oral species that might invade the
gut and contribute to small-intestinal bacterial overgrowth,
which frequently occurs in NASH and cirrhosis [7, 25].
Furthermore, the lower microbial richness and reduced
abundance of butyrate-producing species with anti-in-
flammatory properties (F. prausnitzii, Coprococcus comes,
Lachnospiraceae spp., Ruminoccaceae spp.) suggest that
patients with cirrhosis have a less ‘‘healthy’’ microbiota
[24, 26, 27].
Cirrhotic patients with NASH further demonstrated a
decrease in Veillellaceae and an increase in Bac-
teroidaceae and Porphyromonadaceae families compared
to cirrhotic patients without NASH [19]. Although the
abundance of Enterobacteriaceae was increased in NASH
patients compared to healthy individuals, Enterobacteri-
aceae in NASH patients within a cirrhotic cohort were not
affected. The latter might be due to the high proportion of
Enterobacteriaceae in cirrhotic patients [19, 21, 22].
Interestingly, Bajaj and colleagues showed that the
microbiome in cirrhotic patients with stable disease
remains unaltered over time, suggesting that the composi-
tion of the microbiome can be used as a potential disease
marker [19]. All in all, it appears that different stages of
NAFLD are associated with different microbiota compo-
sitions, although these need to be better defined.
Gut microbiota, bile acids, and hallmarks
of NAFLD
The mechanisms by which gut bacteria affect the various
manifestations of NAFLD have been reviewed recently by
Schnabl et al. [28]. The most relevant insights obtained in
this burgeoning field of research are summarized in Fig. 1.
In view of the accumulating evidence for the role of bile
acids in the treatment of NAFLD [29], we will here focus
on the intimate and reciprocal relation between bile acids
and the gut microbiota.
Bacteria are needed for deconjugation, 7a-dehydroxy-
lation, and dehydrogenation of primary bile acids. Fur-
thermore, the conversion of primary to secondary bile acids
entirely depends on bacteria. Interestingly, germ-free mice
have an increased bile acid synthesis in parallel with a
decreased fecal bile acid output and an expanded circu-
lating bile acid pool [30]. Thus, there appears to be a
relation between the gut microbiota, bile acid synthesis in
the liver, and bile acid uptake in the terminal ileum.
Fibroblast growth factor 19 (FGF19; Fgf15 in rodents)
plays a major role in this by linking events in the gut to
metabolism in the liver [31, 32]. Upon activation of the
Farnesoid X receptor (FXR) by bile acids, FGF19 is pro-
duced in the ileum and secreted into the portal circulation.
In the liver, FGF19 action ultimately results in reduced
transcription of Cyp7A1, the rate-limiting enzyme for bile
acid synthesis [31].
Recent experiments illustrate the interdependence of gut
microbiota and hepatic bile acid synthesis. Bile acids
chenodeoxycholate (CDCA) and cholate (CA) act as FXR
agonists, while tauro-a-muricholic acid (TaMCA) and
tauro-b-muricholic acid (TbMCA) antagonize FXR [30,
33]. In germ-free mice, TbMCA is produced relatively in
excess over CA, suppressing the generation of Fgf15
thereby increasing primary bile acid synthesis [30], with
TbMCA in excess over CA. In conventional mice, the
TbMA/CA ratio is more in favor of CA, limiting bile acid
synthesis. This has implications for the actions of antibi-
otics. The administration of ampicillin to mice decreases
Fgf15, thereby increasing Cyp7a1 expression and the
synthesis of primary bile acids [30, 34]. Miyata et al. [35]
explain the reduced Fgf15 expression by a lack of sec-
ondary bile acids in antibiotic-treated mice. A more likely
explanation is that the TbMCA/CA ratio increases under
antibiotics, causing decreased Fgf15 expression and
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increased bile acid synthesis [30]. Of note, humans do not
produce TaMCA and TbMCA and therefore the effect of
antibiotics on bile acid synthesis in humans may not be the
same as in mice.
Bile acids have a direct antimicrobial effect and affect
microbiota composition [36, 37]. For example, adminis-
tration of CA to rats induced outgrowth of bacteria in, for
example, the genus of Clostridia. These efficiently trans-
form primary bile acids into deoxycholic acid (DCA) by
7a-dehydroxylation [37]. These changes are similar to the
changes seen with a high fat diet. Furthermore, bile duct
ligation in mice induces bacterial overgrowth, mucosal
injury, and bacterial translocation [38, 39]. Lack of FXR-
mediated production of bacteriostatic angogenin1 may play
a role in this, but the details need to be elucidated. Patients
with advanced cirrhosis have a reduced fecal concentration
of total bile acids and a predominance of primary bile acids
[21]. Advanced cirrhotics also have a higher abundance of
Enterobacteriaceae and a decrease of Clostridia [19].
These intestinal bile acid alterations may contribute to
changes of the microbiota. One can argue that in cirrhotics
with a contracted bile acid pool, FXR activation in the
ileum will be reduced. This leads to upregulation of the
apical sodium-dependent bile salt transporter in the ter-
minal ileum, reducing spill-over of bile acids from ileum to
cecum. Bile acids in the cecum have a strong effect on 7a-
dehydroxylating Clostridia [21]. Reduction of the cecal/-
colonic bile acid concentration therefore decreases con-
version of primary bile acids into DCA and LCA
(lithocholic acid).
In contrast, NAFLD-inducing high fat diets (HFD) in
mice increase the conversion of primary to secondary bile
Table 2 Significant microbiota composition changes in cirrhosis
Disease comparison Samples Microbiota variations (family_genus) Techniques References
Healthy (n = 25) versus cirrhotic compensated outpatients
(n = 121), cirrhotic decompensated outpatients
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acids. DCA has pro-inflammatory and DNA-damaging
properties. Yoshimoto et al. [40] report that DCA induces a
‘senescence-associated secretory phenotype’ in hepatic
stellate cells. Among the secretory products are IL-6 and
PAI-1, factors known to induce cancer and obesity [41].
However, diet-induced obesity by itself is not enough to
induce hepatocellular cancer (HCC) in mice; it was the
combination of HFD and treatment with a carcinogen that
was required. The role of DCA in this model was shown by
administration of an inhibitor of 7a-dehydroxylation, which
decreased serum DCA concentration and HCC development.
In contrast, adding DCA to the HFD increased HCC
development [40], the ultimate consequence of NAFLD.
From these studies it is clear that bile acids are major
players in the interaction between the gut microbiota and
the host. Bile acids affect signaling paths, not only those
mediated by FXR and FGF19, but also pathways regulated
by the xenobiotic receptor PXR, the vitamin D receptor
VDR, the G protein-coupled transmembrane receptor TGR,
the muscarinic receptor, and the conjugated bile acid
receptor [42]. These receptors affect metabolism in a wide
variety of cells and organs both within and outside the
enterohepatic circulation. For drug development, this new
knowledge provides opportunities and challenges. Little
attention has been paid yet to the effect of new potent FXR
agonists like obeticholic acid on the microbiota. In view of
the effects these drugs have on bile acid metabolism and
FGF19 expression, they likely will also affect the micro-
biota. Furthermore, bile acid-mediated activation of TGR5
induces secretion of the glucose homeostasis regulating
hormone glucagon-like peptide-1 (GLP-1) [43], which
levels are decreased in NAFLD patients [44]. Other
microbial metabolites such as indole and butyrate are also
able to promote GLP-1 secretion [45, 46], and modulation
of the gut microbiota by prebiotics or antibiotics affects
GLP-1 secretion as well [46–48]. This further underscores
the close interaction between the gut microbiota, bile acids,
and gut hormones involved in metabolism.
How to study and interpret microbiota
To interpret the relevance of published data on microbiota
in NAFLD, both the characterization of the disease and the
type of microbial assays employed need to be taken into
account. Importantly, the intestinal microbiota composition
can be affected by even small changes in experimental
methods at several steps from sample collection to statis-
tical analysis, resulting in a different outcome of apparently
identical studies. The most crucial technical and analytical
aspects of microbial profiling, i.e. factors that may influ-
ence the results and/or result in possible bias, will be dis-
cussed here.
Sampling and storage
It is essential that sampling and storage methods do not
modify microbiota composition by themselves. An
important consideration in this respect concerns the type of
samples collected, which are commonly stool or endo-
scopic biopsies. Stool samples are non-invasive and easy to
obtain. However, the colonic mucosal microbiota has been
shown to deviate considerably from stool microbiota, also
in cirrhotic patients [49–51]. Moreover, whereas micro-
biota composition along the colon was considered
homogenous only a decade ago [50, 51], recent high-
throughput microbial profiling techniques revealed that the
mucosal microbiota varies along the length of the gut [52,
53].
Immediate freezing of microbiota-containing samples is
regarded the gold standard for long-term storage. However,
this is a logistic challenge in large cohort studies which
usually rely on fecal swabs [54]. Fecal swabs are com-
monly stored for short-term at room temperature in specific
media in which obligate anaerobes can survive [55].
Recently, the impact of different sampling (fecal aliquots
and fecal swabs) and storage techniques (-80, -20, ?4 C
for 1 week and RT for 24 h) on fecal microbiota compo-
sition was examined in healthy and diseased individuals
[56]. Although no significant effect of storage temperature
on microbiota composition was observed during transport
(24 h), fecal swabs stored in Cary-Blair medium showed an
enrichment of Ruminococcus and Enterobacteriaceae in
comparison to fecal aliquots stored at -80 C. Therefore, it
is recommended to use a single uniform method within one
study to minimize possible bias. Additionally, it is crucial
to only compare results that have been obtained with the
same sample methodology and from the same type of
sample.
As for the design of studies, large-scale well-defined
prospective cohorts of patients that have been carefully
phenotyped are essential. In these studies, factors known to
influence gut microbiota composition should be taken into
account. In particular, diet and use of antibiotics, probi-
otics, and prebiotics should be well-documented. Further-
more, sex-specific differences in the human colonic
microbiota have recently been shown [52] and should be
considered when setting up microbiota studies.
Microbial screening techniques
The human gut mainly harbors strictly anaerobic microbial
species that are difficult to culture. Therefore, several
culture-independent techniques have been introduced in
recent decades to analyze composition and complexity of
the intestinal microbiota. These techniques include (quan-
titative) polymerase chain reaction [(q)PCR], PCR
Hepatol Int (2015) 9:406–415 411
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followed by denaturing gradient gel electrophoresis, fluo-
rescent in situ hybridization (FISH), and DNA microarrays
that hybridize ribosomal RNA (rRNA) sequences with
probes.
Although these methods are useful for rapid microbial
profiling, they usually do not provide detailed taxonomic
data. For that reason, the most important techniques
nowadays are high-throughput next-generation sequencing
followed by bioinformatics analysis. These sequence
methods are commonly based on analysis of the 16S rRNA
gene which is present in all bacteria and archaea, consisting
of nine unique hypervariable regions (V1–V9) and bor-
dered by highly conserved regions [57]. Despite the fact
that other genes have been suggested, sequencing of 16S
rRNA remains the gold standard to analyze the microbiota
in view of the completeness of reference databases, low
costs, and advanced bioinformatics software available.
Different next-generation sequencers can be used to ana-
lyze the 16S rRNA gene. However, the majority utilizes
either Illumina sequencing (Illumina Inc., San Diego, CA)
or 454 pyrosequencing (Roche, Brandfort, CT). These
widely popular approaches have distinct coverage ratios,
sequence lengths, and construction mechanisms. 454
pyrosequencing generates longer sequences which increa-
ses taxonomic accuracy, whereas Illumina provides higher
coverage at lower cost per sample [58]. It should be noted
that the selection of primers, the number of sequences,
costs, and aim of the experiment are strongly interdepen-
dent. Therefore, it is essential to balance these factors to
achieve the optimum amount of information.
Although 16S sequencing is the most commonly used
technology in microbiome studies, it is important to
understand its limitations. Differences in DNA extraction
methods, PCR errors, and discrepancy in 16S gene copy
numbers all affect the proportions of bacteria detected [59–
61]. The latter leads to bias in the detection of unknown or
unclassified bacteria (dead or alive) and taxonomic char-
acterization. Moreover, both 454 pyrosequencing and
Illumina display sequencing error rates; pyrosequencing is
associated with relatively more insertions and deletions,
whereas Illumina has more mismatches [62, 63]. Therefore,
it is crucial to consider standardized control sequences to
estimate the exact error rate for each experiment. Addi-
tionally, despite the fact that sequencing of 16S rRNA
provides insight into overall microbiota composition, it
does not provide data on their functions and interactions.
Finally, it should be noted that it was recently found that in
certain conditions, next-generation sequencing data were
found to be less representative of the ‘real’ microbiota than
culture-based methods [64].
Metagenomics and metabolomics
As opposed to sequencing of marker genes such as the 16S
rRNA gene, sequencing of the entire genomic content of
microorganisms (the ‘microbiome’) provides more specific
information on their potential functional roles. These
metagenomic or metatranscriptomic analyses, referred to as
shotgun sequencing, are especially appropriate for linking
microbial communities with functional potential and
activity in the human gut. In addition, metabolomics—the
quantitative assessment of metabolic responses of organ-
isms to genetic or pathophysiological changes—is a pow-
erful approach and also key to unraveling specific host-
microbe interactions. Metagenomic approaches relate the
microbiome to phenotype changes in disease, whereas
metabolomic approaches relate the metabolic profile with
disease phenotypes [65]. The latter analyses are principally
based on proton nuclear magnetic resonance (1H-NMR)
spectroscopy and mass spectrometry methods. Ideally,
these analytical techniques should be complemented for the
most detailed characterization of microbial metabolites
obtained from feces, blood, urine, or intestinal tissues. In
contrast to just sequencing the microbiota, shotgun-se-
quencing and metabolomics require direct freezing of fecal
samples.
Analysis with bioinformatics
16S rRNA gene sequences can be analyzed with several
tools, especially with QIIME [66] and Mothur software
[67], which are reviewed in detail elsewhere [65, 68, 69].
These approaches produce phylogenetic trees and assess-
ments of bacterial diversity within samples (a-diversity)
and between samples (b-diversity). To this end, sequences
are clustered into taxonomic groups, referred to as opera-
tional taxonomic units (OTUs), by comparing them across
samples (de novo) or to reference data such as Greengenes
[70]. Importantly, a reference-based approach provides a
more straightforward interpretation and enables the com-
parison of data with different sequenced regions of the 16S
rRNA gene. However, a crucial consideration and limita-
tion of this technique is the common existence of unclas-
sified bacteria in these databases and the complex
taxonomic clustering including discrimination of related
bacterial types. To reduce the effect of sequencing errors, it
is recommended to disable the formation of new clusters
with sequences that were not detected in any reference
database. Fortunately, the increasing developments in the
field of microbiota contribute to a high rate of classifying
and discovering novel bacteria species.
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Conclusion and perspectives
Our progressive knowledge of the role of the gut micro-
biota in NAFLD is rapidly expanding due to improved
DNA sequencing techniques. However, currently available
studies show a marked discrepancy in results which is
likely related to small sample size, variability in patient
cohorts, and limited phenotyping of liver disease. Different
sampling techniques and analysis methods likely also
underlie the lack of consistent data. The key challenge now
is to execute large-scale prospective studies with carefully
phenotyped subjects; sequential samples should be
obtained to demonstrate causality of gut microbiota chan-
ges in the etiology of NAFLD/NASH. In addition, diet,
medicine use, and sampling methods should be well doc-
umented and considered before drawing conclusions.
Importantly, metatranscriptomic and metabolic approaches
are lacking and are urgently needed to assess the specific
functional role of a certain microbial community. Provid-
ing insight into these aspects will help in understanding
NAFLD pathophysiology and might eventually yield non-
invasive biomarkers. However, next-generation sequencing
techniques are currently not able to characterize the entire
microbiota and their reproducibility has to be increased to
use the microbiome as a diagnostic biomarker. Novel
molecular methods, such as the promising IS-pro tech-
nique, may contribute to this [71]. Despite these challenges
and the fact that the progression of NAFLD relies on
multiple hits, the intestinal microbiota appears to represent
an important factor that contributes to several aspects of
NAFLD, and should be considered in any future mecha-
nistic study.
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